Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093027 | 0.82 | MAPT (0.35) | RAB9AKMT2A | |
| SCHEMBL6091627 | 0.78 | HTT (0.37) | RAB9AALDH1A1KMT2A | |
| SCHEMBL6092286 | 0.73 | POLB (0.34) | ALDH1A1HSD17B10KMT2A | |
| SCHEMBL6093531 | 0.72 | IDO1 (0.32) | KMT2A | |
| SCHEMBL6093204 | 0.71 | TDP1 (0.43) | TDP1RAB9AALDH1A1MMP3MCOLN3 | |
| SCHEMBL6091521 | 0.70 | PPARA (0.44) | ALDH1A1KMT2A | |
| SCHEMBL6091531 | 0.69 | MAPT (0.36) | ALDH1A1KMT2A | |
| SCHEMBL6093390 | 0.64 | MMP9 (0.46) | MMP9MMP13RAB9AALDH1A1MAPK1 | |
| SCHEMBL19900168 | 0.64 | ALDH1A1 (0.58) | MMP9MMP13RAB9AALDH1A1MAPK1 | |
| SCHEMBL6090959 | 0.63 | P4HB (0.38) | RAB9AALDH1A1HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006004903-A2 | 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ATHEROGENICS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | TDP1 2855/4885MMP9 2936/4885MMP13 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.